Abstract:4068 Background: The lack of effectiveness of a cytotoxic agent for intra-arterial use in HCC has been a major limitation for improved outcomes. Idarubicin, an anthracycline-based drug, is currently used as the first-line treatment option for acute myeloid leukaemia. Incredibly, a previous study showed that idarubicin has better anti-tumor effects on HCC compared with oxaliplatin and 5-fluorouracil in vitro, and two single-arm studies of idarubicin lipiodol TACE reported good therapeutic outcomes and acceptable adverse drug reactions. Methods: This randomized, double-blind, parallel controlled, phrase IV, multicenter trial was conducted from July 2020. Patients with BCLC stage B HCC were randomly assigned in a 1:1 ratio to receive TACE loaded with 10 mg idarubicin (IT group) or 40 mg epirubicin (ET group). The sample size of 120 was needed in each group according to calculation. The primary endpoint was progression-free survival (PFS, defined as the time from randomization until progression or death from any cause). The secondary endpoints were overall survival (OS, defined as the date of randomization to death from any cause), objective response rate (ORR, the proportion of patients with complete response or partial response according to mRECIST), and adverse events. A single interim analysis was planned when appropriately 1/3 (33.3%) of the required 240 patients. To control the type I error rate at the interim analysis, superiority boundaries that were based on Pocock spending function 24 were a P value of less than 0.022 for PFS. The deadline for interim analysis of data is October 1, 2021. Results: Overall, 103 patients (mean age: 56.6 years±11.4; 12 women and 91 men) were randomly assigned to receive either TACE with Idarubicin-eluting beads (n = 50) or TACE with Epirubicin-eluting beads (n = 53). The PFS and OS were not mature on October 1, 2021. The median PFS was significantly longer in the IT group than in the ET group (HR [hazard ratio] = 0.32, P < 0.001). PFS rates were 82.4% and 43.9% at 6 months, and 53.7% and 18.9% at 12 months in IT and ET groups, respectively. The median OS was longer but not significant in the IT group than in the ET group (HR = 0.52, P = 0.058). OS rates were 90.2% and 76.5% at 6 months, and 61.6% and 47.3% at 12 months in IT and ET groups, respectively. TACE with Idarubicin-eluting beads did not improve ORR compared to TACE with Epirubicin-eluting beads according to mRECIST (80.0% vs. 62.3%, P = 0.048). The incidence of myelosuppression was higher in the ET group than in the IT group (22.6% vs. 6.0%, P = 0.024). No difference was observed in other treatment related adverse events. Conclusions: This study proved that Idarubicin could be a good safety profile and superior PFS and ORR than Epirubicin when used as part of a TACE regimen for BCLC B stage HCC. Longer follow-up is needed to confirm this conclusion. Clinical trial information: ChiCTR2000034758.

Transarterial Chemoembolization Using Idarubicin Versus Doxorubicin Chemoemulsion in Patients with Hepatocellular Carcinoma (IDADOX): Protocol for a Randomized, Non-inferiority, Double-Blind Trial

Hepatic Resection Versus TILA-TACE in the Treatment of Resectable Hepatocellular Carcinoma: Study Protocol for a Randomized Controlled Trial

NeoTACE: A Multicenter, Randomized Study Evaluating the Efficacy and Safety of Neoadjuvant HAIC for TACE Plus Donafenib in BCLC B Stage Hepatocellular Carcinoma Outside of Up-to-seven

TIDE: adjuvant tislelizumab plus donafenib combined with transarterial chemoembolization for high-risk hepatocellular carcinoma after surgery: protocol for a prospective, single-arm, phase II trial

Idarubicin-loaded drug-eluting microspheres transarterial chemoembolization for intermediate stage hepatocellular carcinoma: safety, efficacy, and pharmacokinetics

[Clinical Investigation on Transarterial Chemoembolization with Indigenous Drug-Eluting Beads in Treatment of Unresectable Hepatocellular Carcinoma].

TACE with idarubicin-eluting beads compared with TACE with epirubicin-eluting beads in BCLC B-stage HCC: Interim results of a randomized, double-blind, parallel-controlled, phrase IV multicenter study.

Randomized Clinical Trial of Transcatheter Arterial Chemoembolization Plus Radiofrequency Ablation Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma with Intermediate Stage (BCLC Stage B) Hepatocellular Carcinoma Beyond Milan Criteria.

Evaluation of Transarterial Chemoembolization Protocol with Drug-Eluting Beads in Combination with Lipiodol for Hepatocellular Carcinoma: A Single-Center Controlled Study

Comparing the efficacy and safety of HepaSphere drug-eluting bead transarterial chemoembolization combined with hepatic arterial infusion chemotherapy versus hepatic arterial infusion chemotherapy alone in unresectable colorectal liver metastases.

Efficacy and safety of transarterial chemoembolization alone compared to its combination with anlotinib among patients with intermediate or advanced stage hepatocellular carcinoma: a phase II randomized controlled trial

Transcatheter arterial chemoembolization plus Sorafenib versus transcatheter arterial chemoembolization plus Lenvatinib for intermediate hepatocellular carcinoma

Comparison of Drug-Eluting Bead with Conventional Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: a Randomized Clinical Trial.

Comparison of Arterial Infusion Chemotherapy and Chemoembolization for Locally Advanced Hepatocellular Carcinoma: a Multicenter Retrospective Study

Surgical Resection plus Intraoperative Radiofrequency Ablation versus Chemoembolization for the Treatment of Intermediate-Stage (BCLC B) Hepatocellular Carcinoma with Preserved Liver Function: A Propensity Score-Matched Analysis

Lipiodol combined with drug-eluting beads versus drug-eluting beads alone for transarterial chemoembolization of hepatocellular carcinoma: a multicenter study

A Comparison Between Drug-Eluting Bead-Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma: A Meta-Analysis of Six Randomized Controlled Trials.

Hepatectomy versus transcatheter arterial chemoembolization for resectable BCLC stage A/B hepatocellular carcinoma beyond Milan criteria: A randomized clinical trial

CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study

Hepatic Arterial Infusion Chemotherapy with Oxaliplatin Plus Raltitrexed as an Alternative Option in Advanced Hepatocellular Carcinoma Patients with Failure of, or Unsuitability for, Transarterial Chemoembolization

Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial